Single versus double autologous stem cell transplantation and lenalidomide maintenance versus no maintenance therapy in newly-diagnosed patients with multiple myeloma: a real-life, vintage snapshot after twenty-three years from the Rete Ematologica Pugliese [0.03%]
单倍体自体干细胞移植与来那度胺维持治疗对比在初诊多发性骨髓瘤患者中：来自Puglia血液学工作组23年的真实生活快照
Nicola Di Renzo,Emanuela Resta,Michelina Dargenio et al.
Nicola Di Renzo et al.
Autologous stem cell transplantation (ASCT), doubled in selected cases, followed by lenalidomide maintenance (LM) remains the standard treatment after induction therapy for newly diagnosed, transplant eligible patients with multiple myeloma...
A comprehensive analysis of B symptoms reveals prognosis and heterogeneity across different sites of diffuse large B-cell lymphoma [0.03%]
全面分析B症状可揭示不同部位弥漫性大B细胞淋巴瘤的预后和异质性
Chaoling Wu,Yongjun Zhang,Fan Yang et al.
Chaoling Wu et al.
Diffuse large B-cell lymphoma (DLBCL) is a highly aggressive form of non-Hodgkin lymphoma. B symptoms, including fever, night sweats and weight loss, are often overlooked but carry prognostic significance. The primary site of DLBCL also pla...
Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) therapy in diffuse large B-cell lymphoma in patients aged 80 years or older: a real-world study [0.03%]
聚胶质体维多汀、利妥昔单抗、环磷酰胺、多柔比星和泼尼松(Pola-R-CHP)治疗≥80岁弥漫性大B细胞淋巴瘤患者的疗效及安全性：一项真实世界研究
Toshiki Yamada,Nobuhiko Nakamura,Hideko Goto et al.
Toshiki Yamada et al.
Diffuse large B-cell lymphoma (DLBCL) predominantly affects older adults, with an increasing proportion of patients aged ≥ 80 years. Although the POLARIX trial demonstrated improved progression-free survival with polatuzumab vedotin (Pola)...
Understanding challenges and barriers to quality end-of-life care for patients with hematologic malignancies: a GIMEMA survey [0.03%]
意大利GIMEMA联盟血液系统恶性肿瘤患者终末期高质量护理的现状及所面临的挑战和障碍调查研究报告
Leonardo Potenza,Fabio Efficace,Eleonora Borelli et al.
Leonardo Potenza et al.
Patients with hematologic malignancies often receive aggressive end-of-life (EOL) care, which may be partly related to hematologists' discomfort with discontinuing aggressive treatments at EOL. It is therefore important to investigate how h...
Updated Egyptian national guidelines for management of hemophilia A in children & adolescents [0.03%]
埃及儿童及青少年A型血友病管理国家指南更新
Galila Mokhtar,Amal El-Beshlawy,Mohsen El Alfy et al.
Galila Mokhtar et al.
To improve patient advocacy in hemophilia, the World Federation of Hemophilia (WFH) recommends establishing a National Hemophilia Committee (NHC), developing standards and guidelines, broadening the community through including people with v...
Zanubrutinib plus salvage chemotherapy in patients with refractory/relapsed diffuse large B-cell lymphoma non-candidate for autologous stem cell transplantation: A retrospective study [0.03%]
zanubrutinib联合挽救化疗治疗自体造血干细胞移植不合格的复发/难治弥漫大B细胞淋巴瘤患者：一项回顾性研究
Sha He,Jie Sun,Dani Zhong et al.
Sha He et al.
Salvage chemotherapy followed by autologous stem cell transplantation (auto-SCT) is effective for relapsed or refractory DLBCL (R/R DLBCL), but many patients are ineligible due to age, comorbidities, tolerance, economy and other factors. Za...
Impact of FLT3 mutation on its intracellular localization and implications for anti-leukemia strategy [0.03%]
FLT3突变对其胞内定位的影响及对白血病治疗的启示
Fei Song,Long Su,Sujun Gao
Fei Song
Fms-like tyrosine kinase 3 (FLT3) mutation is one of the most prevalent molecular abnormalities in acute myeloid leukemia (AML), with FLT3 internal tandem duplication (FLT3-ITD) mutation being the major mutated form. AML patients with FLT3-...
Early-life clinical and hematological profiles: a comparative study of children with and without sickle cell disease in the first three years of life [0.03%]
早期临床和血液学特征：生命最初三年患有镰状细胞病儿童与未患病儿童的比较研究
Siana Nkya,Isihaka Mahawi,Rehema Shungu et al.
Siana Nkya et al.
Sickle cell disease (SCD) has been associated with significant morbidity and mortality, particularly in early childhood. Understanding the hematological and clinical outcomes during the early years of life is crucial for guiding interventio...
"B" symptoms and CBV conditioning negatively impact survival in mantle cell lymphoma patients undergoing autologous stem cell transplantation [0.03%]
B细胞症状和CBV预处理对接受自体干细胞移植的套细胞淋巴瘤患者生存率的负面影响
Karolina Chromik,Agata Wieczorkiewicz-Kabut,Patrycja Zielińska et al.
Karolina Chromik et al.
Introduction: Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma with limited curative options. Autologous stem cell transplantation (ASCT) is widely used as consolidation in younger, fit patients. Th...
Correction to: Association between HLA-DRB1*04, HLA-DQB1*03, and HLA-DQB1*06 with alloimmunization in transfusion-dependent patients with thalassemia: the first case-control study in Iran [0.03%]
对HLA-DRB1*04，HLA-DQB1*03和HLA-DQB1*06与输血依赖性患者溶血性输血反应的关联在中国的第一例对照研究的订正通知
Masoud Kargar,Gholam Abbas Kaydani,Bijan Keikhaei et al.
Masoud Kargar et al.
Published Erratum
Annals of hematology. 2025 Oct 8. DOI:10.1007/s00277-025-06678-3 2025